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Abstract 
Background: The long noncoding RNA Xist is critical for initiation and establishment of X‑chromosome inactivation 
during embryogenesis in mammals, but it is unclear whether its continued expression is required for maintaining 
X‑inactivation in vivo.
Results: By using an inactive X‑chromosome‑linked MeCP2‑GFP reporter, which allowed us to enumerate reactiva‑
tion events in the mouse brain even when they occur in very few cells, we found that deletion of Xist in the brain after 
establishment of X‑chromosome inactivation leads to reactivation in 2–5% of neurons and in a smaller fraction of 
astrocytes. In contrast to global loss of both H3 lysine 27 trimethylation (H3K27m3) and histone H2A lysine 119 mon‑
oubiquitylation (H2AK119ub1) we observed upon Xist deletion, alterations in CpG methylation were subtle, and this 
was mirrored by only minor alterations in X‑chromosome‑wide gene expression levels, with highly expressed genes 
more prone to both derepression and demethylation compared to genes with low expression level.
Conclusion: Our results demonstrate that Xist plays a role in the maintenance of histone repressive marks, DNA 
methylation and transcriptional repression on the inactive X‑chromosome, but that partial loss of X‑dosage compen‑
sation in the absence of Xist in the brain is well tolerated.
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Background
X-chromosome inactivation in female mammals equal-
izes the autosome to X-chromosome gene dosage in 
males (XY) and females (XX) [1]. Two waves of X-inac-
tivation are observed during early mouse embryogenesis, 
an extensively studied model for X-inactivation in mam-
mals (reviewed in [2, 3]). An initial wave of inactivation 
occurs at the 2–4-cell stage in the embryo, specifically on 
the paternal X-chromosome (Xp) [4, 5]. This imprinted 
X-inactivation pattern remains throughout development 
in the extraembryonic tissues, which give rise to the tro-
phectoderm and primitive endoderm, but it is reversed at 
a late blastocyst stage in the inner cell mass (ICM) [6], 
which forms the embryo proper. Following reactivation 
of the Xp, a second wave of inactivation in the ICM after 
implantation (E 5.5–6.5) randomly inactivates either the 
maternal X (Xm) or Xp [5, 6], generating a mosaic inacti-
vation pattern that is clonally propagated and maintained 
through the lifetime of the animal.
The process of X-inactivation can be divided into four 
stages: initiation, spreading, establishment and mainte-
nance [2]. X-inactivation initiates with the expression 
of the long noncoding RNA, Xist (X-inactive-specific 
transcript), from the chromosome to be inactivated [7, 
8], which spreads in cis along the entire chromosome 
and recruits additional silencing factors, which together 
establish stable repression of that chromosome for the 
lifetime of the cell and its progeny (reviewed in [9]). 
Among repressive factors recruited to the Xi by Xist are 
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the polycomb repressive complexes 1 and 2 (PRC1 and 
PRC2), which catalyze monoubiquitylation of lysine 119 
on histone H2A (H2AK119ub1) and trimethylation of 
lysine 27 on histone H3 (H3K27me3) ([10], reviewed in 
[11]), respectively, and many others identified through 
different oligonucleotide pull-down screens [12–14]. 
DNA methylation is thought to be a later event in the 
process of X-inactivation [15]. The expression of Xist 
continues during the maintenance phase, generating a 
cloud of Xist that surrounds the Xi.
The essential role of Xist and dosage compensation in 
mouse embryonic development has been established by 
genetic analysis of Xist mutations. Xist-loss-of-function 
mutations inherited from the father lead to early, female-
specific, embryonic lethality due to loss of imprinted 
X-inactivation and failure to establish XCI in the extra 
embryonic tissues [16]. A poorly developed trophecto-
derm, which fails to supply the conceptus with the nec-
essary nutrients, is thought to be the primary reason for 
the embryonic lethality in females lacking paternal Xist, 
given that the X-chromosome inactivation in the inner 
cell mass is preserved due to inactivation of the Xm with 
intact Xist [5, 6]. In contrast to the inheritance of pater-
nal Xist mutation, which is lethal, maternal Xist mutation 
in female embryos is tolerated because imprinted inac-
tivation in the extraembryonic tissues is preserved and 
because XCI in the embryo proper, while infeasible on 
the Xm, can be accomplished by skewed inactivation of 
the Xp [5, 6, 16]. Yang et al. [17] recently deleted Xist spe-
cifically in the inner cell mass, circumventing the essen-
tial role of Xist in the extraembryonic tissues and early 
embryonic lethality, to further examine the role of Xist in 
establishment of random X-inactivation and the role of 
dosage compensation during development. Even though 
these animals fail to establish a properly inactivated Xi, 
displaying partial loss of dosage compensation, organo-
genesis was grossly normal with many pups surviving to 
term. However, all the animals succumb by 3  weeks of 
age, consistent with decreased overall fitness due to X to 
autosomal imbalance. These results together revealed a 
critical role for Xist during initiation and establishment 
of both imprinted and random X-inactivation.
While the critical role of Xist in initiation and estab-
lishment of X-chromosome inactivation is well sup-
ported by mouse genetic studies, the role of Xist in the 
maintenance of X-chromosome inactivation is not as 
clearly defined. Deletion of Xist in the mouse hematopoi-
etic compartment during the maintenance phase leads to 
highly penetrant leukemia, consistent with an important 
role for Xist in suppressing hematologic malignancies 
[18]. Furthermore, two unbiased genetic screens using 
X-linked reporter genes on the Xi identified Xist and 
Xist regulators as factors required for maintaining the 
silenced state on the Xi [19, 20]. However, other studies 
examining X-reactivation in human or mouse differenti-
ated cells found no requirement for Xist in maintaining 
repression on the Xi. Even though expression of Xist as 
well as Xist cloud formation is normally present during 
the maintenance phase, genetic ablation of Xist in mouse 
fibroblasts, without concomitant DNA demethylation, 
did not result in appreciable Xi reactivation [21]. Simi-
lar conclusion that both Xist deletion and DNA dem-
ethylation are needed for Xi reactivation was drawn in a 
recent study that employed global transcriptional profil-
ing across the X-chromosome in the mouse brain [22]. 
Different outcomes of these studies, which might reflect 
the use of different model system or methods for measur-
ing X-reactivation, make it difficult to draw a conclusion 
about the role of Xist in maintenance of Xi.
To clarify the role of Xist in the maintenance of random 
X-inactivation, we examined the effect of deletion of Xist 
on the Xi in the developing mouse brain using a Nestin-
Cre driver [23], expressed during the time window after 
random Xi has been well established. Critically impor-
tant for this study, because we suspected that reactivation 
might occur in only small fraction of cells, we employed 
a MeCP2-EGFP reporter gene on the Xi, which is driven 
by the endogenous MeCP2 promoter known to be highly 
active in neurons when on the Xa [24]. We found that 
deletion of Xist leads to nearly complete loss of H3K27m3 
and H2AK119ub1, consistent with the proposed role of 
Xist in the recruitment of PRC1 and PRC2 to the Xi [11]. 
However, despite loss of both Xist and these repressive 
histone modifications, the MeCP2 reporter gene on the 
Xi was reactivated in only 2–5% neurons. Animals toler-
ated this partial loss of dosage compensation in the brain 
surprisingly well, without increased mortality, fertility or 
obvious neurologic defects. Our results unequivocally 
demonstrate that continued expression of Xist plays a 
role in maintaining faithful transcriptional repression of 
the Xi in vivo but that partial loss of dosage compensa-
tion in the absence of Xist in the brain is well tolerated.
Results
As discussed previously, female mice that inherit mater-
nal Xist-loss-of-function mutations exhibit exclusive 
inactivation of the Xp. We exploited this X-inactiva-
tion pattern to generate a model in which an X-linked 
MeCP2-EGFP reporter gene is uniformly silenced in all 
cells. We employed two Xist-loss-of-function mutations: 
 Xistfl, containing a deletion of the promoter and the first 
three exons of Xist [25], and  Xisttm5Sado, containing a 
deletion of the proximal A repeat of Xist, which causes 
loss of Xist expression [26]. As both of these alleles were 
previously shown to confer inability to inactivate X-chro-
mosome and yielded the same results in our studies, we 
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refer to them collectively as  Xistmut. We crossed females 
heterozygous for  Xistmut with males carrying EGFP 
reporter fused at the C terminus to MeCP2 to obtain 
 (Xistmut MeCP2) maternal (m)/(Xist MeCP2-GFP) pater-
nal (p) females (Fig.  1a). While MeCP2-EGFP is highly 
expressed throughout brain of MeCP2-GFP/MeCP2 
females, we found no expression in  (Xistmut MeCP2)m/
(Xist MeCP2-GFP)p females (Fig.  1b), consistent with 
uniform silencing of the MeCP2-GFP transgene on the 
Xp. RT-qPCR using primers that amplify the EGFP tran-
script confirmed these histology results (Fig.  1c). Given 
complete skewing of X-chromosome inactivation and 
Fig. 1 a Mutation of Xist on the maternal X‑chromosome leads to skewed inactivation of the MeCP2‑GFP reporter gene on the paternal 
X‑chromosome. b GFP immunohistochemistry with and without hematoxylin (+H and −H) in the brain of the MeCP2  Xistmut/MeCP2‑GFP female 
demonstrates no GFP staining. The brain of the MeCP2/MeCP2‑EGFP animal exhibits a bimodal nuclear staining for GFP reflective of random 
MeCP2‑EGFP inactivation. c MeCP2‑EGFP mRNA level in the brain from MeCP2  Xistmut/MeCP2‑EGFP relative to MeCP2‑EGFP/MeCP2 analyzed by 
RT‑qPCR (n = 3 for each group, error bars indicate SD, ***p < 0.001, Student’s t test)
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thus absence of MeCP2-GFP expression, we felt that this 
model would be sufficiently sensitive to detect low levels 
of the reporter gene reactivation that would be obscured 
in a MeCP2/MeCP2-GFP animal, in which large fraction 
of cells expresses MeCP2-GFP as baseline.
We used this experimental system to determine 
whether Xist is required in  vivo for maintaining the 
silenced state of MeCP2-GFP on Xi in brain after silenc-
ing has already been established. After introducing the 
floxed Xist allele  (Xist2lox) [25] to the X-chromosome car-
rying MeCP2-EGFP reporter gene [24], we crossed the 
hemizygous males carrying this X-chromosome MeCP2-
GFP-Xist2lox/y) with heterozygous Xist/Xistmut females 
that also carry the Nestin-Cre transgene to obtain 
 Xistmut/MeCP2-GFP-Xist2lox females with and without 
the Nestin-Cre transgene [23]. Cre-mediated recombi-
nation of the  Xist2lox transgene deletes the promoter and 
first three exons of the Xist gene. Random X-inactivation 
occurs between embryonic days (E) 5.5 and 6.5, whereas 
the Nestin-Cre is expressed in neuronal lineages peaks 
at E 12.5 with little to no detectable expression before 
E 9.5 [23, 27]. Therefore, the female progeny carrying 
Nestin-Cre would excise the paternal Xist2lox allele after 
random X-inactivation has been established, and the 
progeny without Nestin-Cre transgene would serve as lit-
termate controls.
We examined DNA extracted from brain and spleen 
from Nestin-Cre mice and found complete excision in the 
brain and no excision in the spleen (Fig.  2a), consistent 
with the known pattern of Nestin-Cre expression [23]. 
In Nestin-Cre negative control littermates, we observed 
no excision in either of these tissues. RNA-Seq data for 
Xist transcript levels revealed > 20-fold decrease in Xist 
abundance in the RNA extracted from the brains of Nes-
tin-Cre animals compared with their littermate controls 
without Nestin-Cre transgene (Fig.  2b).  Xistmut/  Xist2lox 
Fig. 2 a Nestin‑Cre deletes  Xist2lox allele in the brain but not in the spleen of  Xistmut/MeCP2‑GFP‑Xist2lox female animals. Ethidium bromide‑stained 
gel of PCR products for Xist in the DNA extracted from the indicated tissues in animals with (Cre+) and without (Cre−) Nestin‑Cre transgene. b 
Xist RNA level measured by RNA‑seq in the RNA extracted from the  Xistmut/MeCP2‑GFP‑Xist2lox females with (Cre+) and without (Cre−) Nestin‑Cre 
transgene (n = 3). c  Xistmut/  Xist2lox Nestin‑Cre females that lack Xist in the brain were born at the expected Mendelian frequency (p = 0.36, 
Chi‑square test). d Survival curves of females with Nestin‑Cre transgene (nes +) and their littermates without (Cre−) the transgene (Cre+ n = 18, 
Cre− n = 17, N.S. p = 0.58, log‑rank test). e Two‑week sliding averages of weights in  Xistmut/MeCP2‑GFP  Xist2lox females with (Cre+) and without 
(Cre−) Nestin‑Cre transgene (Cre+ n = 14, Cre− n = 15, (**p < 0.01, Student’s t test, for all successive 2‑week periods for the duration of the 
follow‑up)
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Nestin-Cre females that lack Xist in the brain were born 
at the expected Mendelian frequencies (Fig. 2c) and did 
not exhibit any anatomical defects, and their survival was 
indistinguishable from negative control littermates dur-
ing the follow-up of up to 20 months (Fig. 2d). Further-
more, they successfully bred and gave birth to litters of 
the usual sizes.
The only phenotype we observed in animals carry-
ing Nestin-Cre transgene was reduced weight and body 
size evident throughout their lifespan (Fig. 2e). To deter-
mine whether the weight deficit in Nestin-Cre animals 
is dependent on the excision of the Xist transgene in 
 Xistmut /Xist2lox females, we crossed  Xistmut/Xist females, 
with males heterozygous for Nestin-Cre and compared 
weights of  Xistmut/Xist females with and without Nes-
tin-Cre. The weight deficit of the Nestin-Cre animals 
compared with their littermate controls in the cohort 
of animals without the floxed Xist allele  (XISTmut/XIST, 
Additional file  1 lower panel) was similar to the deficit 
in the cohort of floxed Xist animals  (XISTmut/XIST2lox, 
Additional file 1 upper panel), 2.2 g versus 1.75 g, respec-
tively, at weaning, and 1.2 g versus 1.8 g at 3 months. Ani-
mals with Nestin-Cre transgene had comparable weights 
whether they also have or do not have the  XIST2lox 
transgene, 7.8 ± 0.4  g versus 8.3 ± 0.3  g (p = 0.23, Stu-
dent’s t test), respectively, at weaning and 18.4 ± 0.3 g ver-
sus 18.6 ± 0.2 g (p = 0.48 by Student’s t test), respectively, 
at 3 months. Similar reduction in weight and body size, 
attributed to transgene-induced hypopituitarism and 
dwarfism, has been previously reported for Nestin-Cre 
transgenic animals [28]. We conclude that the reduced 
body weight in the  Xistmut /Xist2lox Nestin-Cre animals is 
caused by the Nestin-Cre transgene and not by the dele-
tion of Xist.
Xist is required for the recruitment of PRC1 and PRC2, 
responsible for monoubiquitylation of lysine 119 on the 
histone H2A (H2AK119ub1) and trimethylation of lysine 
27 on histone H3 (H3K27me3) on the Xi, respectively, 
which are critical for the establishment of XCI [11]. To 
examine whether the maintenance of these repressive 
histone marks depends on Xist expression, we compared 
immunofluorescence (IF) signal for both H2AK119ub1 
and H3K27me3 in brain tissues from Cre+ and Cre− 
animals. As expected, the control Cre− littermates, with 
intact Xist, exhibited punctate staining at the nuclear 
periphery for both H3K27me3 and H2AK119ub1 and 
(Fig. 3a, b), marking the inactive X-chromosome in large 
fraction of cells, 72 ± 6% for H3K27me3 and 49 ± 4% for 
H2AK119ub1, along with diffuse staining throughout the 
nucleus. In Nestin-Cre animals, punctate staining pattern 
for both histone marks was lost in the vast majority of 
cells while the diffuse staining was maintained (Fig. 3a–
c). We conclude that Xist is required for the maintenance 
of both H2AK119ub1 and H3K27me3 repressive marks 
on the Xi.
To determine whether deletion of Xist is required 
for maintaining MeCP2-GFP silencing, we performed 
immunohistochemistry (IHC) for GFP on the brain tissue 
from mice with and without Nestin-driven Cre, alongside 
positive control females (MeCP2-EGFP/MeCP2-EGFP) 
and wild-type control females. Whereas no GFP-positive 
cells were observed in the brains of the Nestin-Cre nega-
tive controls, we found that 1.4–4.0% of cells in the brain 
parenchyma express GFP (Fig.  4a, b). To determine the 
cell types that express MeCP2-GFP, we performed dou-
ble IF stains for GFP with anti-NeuN and with anti-S100b 
antibodies, marking neurons and astrocytes, respectively 
(Fig.  4c). The vast majority of EGFP-positive cells also 
expressed NeuN, demonstrating MeCP2-GFP reactiva-
tion in neurons. While the reactivation of MeCP2 was 
not limited to neurons, as we also observed GFP-positive 
cells among the S-100b expressing astrocytes, the frac-
tion of astrocytes that express GFP was lower compared 
to neurons (0.1–0.2% vs 2.3–4.8%, p < 0.05, Student’s t 
test) (Fig.  4b, c). EGFP expression level in MeCP2 Nes-
tin-Cre animals measured by qPCR was 3.2 ± 0.8% of 
the expression observed animals with the MeCP2-GFP 
reporter gene on the Xa, which is similar to the results 
observed by IHC or IF (Additional file 2A).
The pattern of expression of MeCP2-GFP in Nes-
tin-Cre animals is bimodal, as judged by IHC and IF, 
with cells either fully expressing or not expressing the 
reporter gene, suggesting that silencing of the MeCP2-
GFP remains intact in a large fraction of cells and that 
dosage compensation is largely preserved for this gene 
despite the absence of Xist. To examine the consequences 
of Xist deletion on expression level of other genes on the 
X-chromosome, we compared the RNA expression level 
in brains by RNA-seq in Nestin-Cre-positive animals 
and their Nestin-Cre-negative control littermates. While 
gene expression scatter plots for genes on the autosomes 
did not differ between animals lacking Xist and control 
animals, the scatter plots of the genes on the X-chro-
mosome exhibited an upward shift compared to auto-
somes (Fig.  5a left panel, Additional file  2B), suggesting 
that genes on the X-chromosome were overexpressed 
in the mutants. Cumulative expression plots of the fold 
expression change in the mutant compared to the con-
trols for genes on the X-chromosome exhibited a subtle 
but significant shift to the right compared to the auto-
somes (p < 0.01, Wilcoxon rank-sum test) (Fig. 5a middle 
panel, Additional file  3). Similar comparison of control 
RNA samples showed no difference between X-linked 
and autosomal genes (Additional file 2C). When we ana-
lyzed binned fold expression changes (Fig. 5a right panel) 
of the same data, we observed a subtle shift to the right, 
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Fig. 3 IF for a H3K27me3 and b H2AK119ub1 in the brain of animals without (control) and with Xist deletion (mutant). Punctate nuclear staining for 
both H3K27me3 and H2AK119ub1 is abolished by Xist deletion. c Percentage of cells in the brain with punctate staining for the indicated histone 
modification is severely reduced in animals lacking Xist (n = 3 for each group, error bar indicates SD, **p < 0.01, ***p < 0.001, Student’s t test)
(See figure on next page.)
Fig. 4 a GFP IHC in different brain regions including cortex, hypocampus, brainstem and cerebellum (clockwise starting from left upper panel) of 
Nestin‑Cre+  Xistmut/MeCP2‑GFP  Xist2lox animals lacking Xist in the brain. Bar indicates 80 µm. b Percentage of GFP‑positive cells in the indicated 
brain regions in all cells, NeuN‑positive neurons and S100b‑positive astrocytes (n = 4, error bar indicates SD, neurons vs astrocytes, *p < 0.05, 
Student’s t test). c Reactivation of MeCP2‑GFP reporter gene in neurons and astrocytes in brains from Nestin‑Cre+  Xistmut/MeCP2‑GFP  Xist2lox 
animals. Double IF for GFP and NeuN (upper panel) and for GFP and S100b (lower panel) demonstrates GFP IF in both NeuN‑positive neurons and 
S100b‑positive astrocytes
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averaging 0.04, in the expression level relative to the 
expression levels on the autosomes upon Xist deletion. 
We conclude that deletion of Xist leads to an increase in 
the expression of genes on the X-chromosome but the 
magnitude of the overexpression was subtle, suggesting 
that other genes are reactivated in only small fraction of 
cells, similarly to what we have observed with MeCP2.
As already shown in Fig. 4b, we observed that the level 
of reactivation of the MeCP2-GFP reporter in neurons 
is approximately one order of magnitude higher com-
pared to the level of reactivation in astrocytes (2–5% vs 
0.1–0.2%). Thinking that this might reflect the higher 
level of MeCP2 expression in neurons compared to 
astrocytes, we hypothesized that, after transcriptional 
silencing is perturbed by deletion of Xist, more potent 
transactivation associated with highly expressed genes 
might lead to their more frequent reactivation on the Xi 
compared to genes with low expression levels. To test this 
idea, we divided the genes on the X-chromosome into 
terciles based on their expression level, after excluding 
the genes that are covered with fewer than 20 sequenc-
ing reads whose low expression level precludes accurate 
measurements, and compared the level of reactivation 
among the terciles. The median level of expression in 
the third tercile was similar to the expression level of 
MeCP2, while the expression level in the second and first 
terciles was approximately tenfold and 100-fold lower, 
respectively. The level of gene reactivation was meas-
ured as a fraction of reads in Cre+ samples over total 
reads (Cre+ plus Cre−), which is expected to be > 0.5 
Fig. 5 Analysis of a global transcriptional and b DNA methylation changes on X‑chromosome and autosomes in animals lacking Xist. a Left: Scatter 
plot of RNA expression levels for genes autosomes (black) and X‑chromosome (red) (N = 3 for both mutant and control animals). The genes on 
X‑chromosome exhibit an upward shift relative to autosomes. Middle: Cumulative expression plots of fold expression changes (mutant/control) 
for genes on autosomes (black) and X‑chromosome (red). The genes on X‑chromosome exhibit a rightward shift (p < 0.01, Wilcoxon rank‑sum 
test). Right: Binned fold changes in expression for genes on autosomes (black) and X‑chromosome (red). b Left: Scatter plot of DNA methylation 
abundance at CpG islands on autosomes (black) and X‑chromosome (red) (N = 2 for both mutant and control animals). The CpG islands on 
X‑chromosome exhibit a downward shift relative to CpG islands on autosomes. Middle: Cumulative plots of fold methylation abundance changes 
(mutant/control) for CpG islands on autosomes (black) and X‑chromosome (red) (p < 0.01, Wilcoxon rank‑sum test). Right: Binned fold changes in 
methylation abundance at CpG islands on autosomes (black) and X‑chromosome (red)
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if Xist deletion causes loss of repression on the Xi. The 
fraction of reads in Cre+ samples for genes in the third 
tercile was higher compared to genes in the first tercile 
(0.509 ± 0.047 vs 0.495 ± 0.096, p = 0.008, Student’s t 
test), which corresponds to an average increase of 3% in 
the expression level for the genes in the third tercile, sim-
ilar in magnitude to the level of reactivation we observed 
for MeCP2. The middle tercile exhibited a reactivation 
similar to the third tercile and higher than the first tercile 
(0.508 ± 0.047 vs 0.495 ± 0.096, p = 0.015, Student’s t test) 
(Fig.  6a). Similar results were obtained when the genes 
were divided into quartiles, with the genes from the sec-
ond to fourth quartiles exhibiting a progressive increase 
in reactivation level (Fig. 6b). These results demonstrate 
that genes on the Xi that are normally highly expressed 
are more prone to reactivation upon deletion of XIST 
than genes with lower expression levels, with highly 
expressed genes exhibiting a similar magnitude of reacti-
vation as we observed for MeCP2.
We next examined whether Xist deletion changes DNA 
methylation on the X-chromosome. We used the meth-
ylation-dependent restriction enzyme LpnP1 to interro-
gate almost 50% of all CpG sites across the genome, as 
described [29]. CpG island methylation on autosomes, 
examined by scatter plots, did not differ in brains from 
mutants and their wild-type littermates, whereas the 
scatter plots of CpG islands on X-chromosomes exhibited 
a subtle downward shift (Fig.  5b left panel, Additional 
file 2D). This finding suggests overall decreased methyla-
tion on the X-chromosome upon Xist deletion. Cumula-
tive distribution plots of fold changes in methylation of 
CpG islands demonstrated that deletion of Xist reduced 
methylation in a small fraction of CpG islands but also 
increased methylation levels at even smaller faction of 
other CpG islands, with the predominant overall shift 
toward hypomethylation (p < 0.01, Wilcoxon rank-sum 
test) (Fig. 5b middle and right panels, Additional file 4). 
These results suggest that Xist is required for faithful 
maintenance of DNA methylation on the Xi and that its 
loss creates overall decrease in DNA methylation of the 
X-chromosome.
Having observed (1) that Xi exhibits demethylation and 
(2) that highly expressed gene is more prone to reactiva-
tion upon Xist deletion, we wondered whether the extent 
of demethylation, likewise, correlates with the gene 
expression level. To test this idea, we compared changes 
in methylation level on the CpG islands located within 
4 kb of the transcription start site for the genes in the first 
tercile of the expression level, which as a group did not 
exhibit derepression, with the composite of the second 
and third tercile, both of which exhibited derepression. 
We observed that the genes in the later group had on 
average 5% reduction in the methylation level compared 
to the former (0.487 ± 0.133 vs 0.512 ± 0.109, p = 0.045, 
Student’s t test) (Fig. 6c). These results demonstrate that 
the higher level of transactivation associated with highly 
expressed genes is also reflected in a higher level of dem-
ethylation of their CpG islands on the Xi.
Discussion
In this study, we used Nestin-Cre to delete Xist specifi-
cally on the Xi in the developing mouse brain after silenc-
ing has been established, and measured reactivation of 
a MeCP2-EGFP reporter gene on the Xi. The Xm car-
rying an Xist mutation and a wild-type allele of MeCP2, 
combined with the Xp, which carried both a floxed Xist 
allele and the MeCP2-EGFP reporter, ensured that the 
reporter gene and the floxed Xist allele are uniformly on 
Fig. 6 Violin plots of the ratios of the RNA reads in Cre+/Cre+ plus Cre−) animals for X‑linked genes that are divided into terciles (a) and quartiles 
(b) according to their expression level. Each tercile and quartile has 180 and 135 genes, respectively. All p values were calculated using Student’s t 
test. The average ratios for quartiles 1–4 are 0.494, 0.504, 0.508 and 0.510, respectively. The differences among adjacent quartiles are not significant. c 
Changes in CpG island methylation expressed as a ratio of methylation abundance in Cre+/(Cre+ plus Cre−) animals for genes grouped according 
to their expression level, as in (a), with the first tercile compared with an aggregate of the second and the third terciles (*p = 0.045, Student’s t test, 
0.487 ± 0.133 vs 0.512 ± 0.109, N = 180 first tercile, N = 360 combined second and third terciles)
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the Xi. The lack of detectable expression of MeCP2-EGFP 
reporter in the brain enabled detection of reactivation in 
even a small fraction of cells upon Nestin-Cre-mediated 
excision of Xist. Because Nestin-Cre-mediated recom-
bination in neural progenitors occurs well after XCI is 
established, our study addresses the role of Xist during 
the maintenance phase. We found that H2AK119ub1 
and H3K27me3 modifications are largely abolished upon 
deletion of Xist. However, despite the loss of both Xist 
and these histone repressive marks, only 1.4–4.0% of 
all cells in brain parenchyma, or 2.3–4.8% of neurons, 
exhibit reactivation of the MeCP2-EGFP reporter gene.
The pattern of MeCP2-EGFP expression upon loss of 
Xist is bimodal, with most cells exhibiting either full or 
no detectible expression. This result demonstrates that 
MeCP2 silencing is maintained in a large fraction of cells 
either because X-inactivation is intact along the entire 
chromosome in a majority of cells, and the small fraction 
of cells that express MeCP2-EGFP have lost silencing 
along the entire chromosome, or because loss of silenc-
ing occurs only in fragments of the Xi in a larger fraction 
of cells. While we cannot differentiate between these two 
possibilities given a single reporter in our study, we favor 
the latter because different loci on the Xi likely differ in 
their propensity to lose transcriptional repression, with 
genes that are highly expressed more prone to reactiva-
tion compared to genes with lower expression level. We 
believe that the higher level of MeCP2-EGFP reactiva-
tion observed in neurons compared to astrocytes is more 
likely a reflection of higher promoter activity and expres-
sion of MeCP2 in the neurons compared to astrocytes, 
leading to increased reactivation at the MeCP2-EGFP 
locus in neurons, than an intrinsic cell-type difference in 
the ability to keep X-inactivation intact along the entire 
chromosome. This reasoning is supported by our obser-
vation presented in Fig. 6AB that X-linked genes that are 
highly expressed are more prone to reactivation com-
pared to genes with lower expression level.
Many of the repressive factors are recruited to the Xi 
via their interaction with Xist. Among these factors are 
PRC1 and PRC2, which are responsible for deposition 
of the H2AK119ub1 and H3K27m3 repressive marks on 
the Xi [10, 11]. Our observation that these two histone 
modifications are largely abolished upon Xist deletion 
supports the idea that the continued presence of Xist at 
the Xi is required for maintaining PRC1 and PRC2 and 
the associated enzymatic activities at the Xi. However, as 
silencing of the MeCP2 reporter gene was intact in the 
vast majority of cells, it is likely that other factors, once 
recruited to Xi, no longer require Xist to remain on the Xi 
and enforce transcriptional repression. Dnmt1 has been 
identified as another factor that is physically tethered 
to Xi by Xist [14]. Consistently, we found a decrease in 
DNA methylation on the X-chromosome upon deletion 
of Xist in the brain. However, these methylation changes 
were subtle compared to global loss of H2AK119ub1 and 
H3K27m3 repressive marks. Largely preserved methyla-
tion on the Xi makes this modification a likely candidate 
for the maintenance of Xi in the brain in the absence of 
Xist. This possibility is also supported by the previously 
published in  vitro study demonstrating that while dele-
tion of Xist alone resulted in no reactivation, deletion of 
Xist combined with either small molecule inhibition of 
DNA methyltrasferases or a mutation in Dnmt1 resulted 
in a robust reactivation of the reporter gene [21], and by 
the recent mouse study that reported X-chromosome-
wide expression changes when combining Xist deletion 
with pharmacologic inactivation of DNA methyltras-
ferases [22]. These results suggest that DNA methyla-
tion maintains transcriptional repression of the Xi in the 
absence of Xist and that DNA methylation at the Xi dur-
ing maintenance phase is largely independent of Xist.
We show that deletion of Xist leads to subtle changes 
in methylation of CpG islands on the X-chromosome as 
compared to CpG islands on the autosomes. The magni-
tude of these changes was small, similar to what we have 
observed with the transcriptome. Furthermore, the extent 
of gene demethylation at the Xi, similar to derepression, 
correlated with the gene expression level, which sup-
ports the idea that higher level of transactivation associ-
ated with highly expressed genes makes these genes more 
prone to both derepression and demethylation on the Xi. 
Similar observation that transcriptional activators can 
overcome position effect variegation has been reported 
at telomeric loci in S. cerevisiae [30]. Interestingly, while 
the transcription from the X-chromosome was uniformly 
increased upon Xist deletion as compared to autosomes, 
consistent with reduced transcriptional activation on the 
Xi, CpG island methylation changes were bidirectional, 
with some islands demonstrating hypomethylation, and a 
smaller fraction exhibiting hypermethylation in response 
to Xist deletion. Bidirectional changes in CpG islands 
methylation during transcriptional activation on the Xi 
are not surprising because of the known association of 
transcription with hypomethylation of promoter CpG 
islands and hypermethylation of intragenic CpG islands 
[31]. Indeed, X-chromosome inactivation escaper genes 
are characterized by CpG island hypomethylation of their 
promoters and hypermethylation in their gene bodies 
[32].
Despite partial loss of dosage compensation, ani-
mals lacking Xist in the brain appeared healthy, had no 
increased mortality during the follow-up of up to 2 years 
and were fertile delivering the usual litter size. It is 
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widely believed that preserving dosage balance between 
autosomes and sex chromosomes is critical for develop-
ment, organismal viability and fitness across different 
species regardless of the dosage compensation strategy 
employed to achieve the balance [33]. In support of 
this view, genetic perturbation of dosage compensation 
mechanisms in fruit flies (male sex lethal), nematodes or 
mice creates sex-specific embryonic lethality. Our result 
which addresses specifically the maintenance of X-inac-
tivation in the mouse brain, as well as recent studies 
focusing on the establishment of random X-inactivation 
during embryogenesis [17], challenges this view, suggest-
ing instead that perturbation of dosage compensation in 
mice is tolerated better than previously thought.
Conclusions
The importance of Xist for initiation and establishment of 
X-chromosome inactivation and X-chromosome dosage 
compensation during embryogenesis has been well estab-
lished through mouse genetic studies. Our study demon-
strates that Xist also plays a role in the maintenance of 
DNA methylation and transcriptional repression on the 
inactive X-chromosome in  vivo during phase but that 
partial loss of X-dosage compensation upon Xist deletion 
in the brain, with reactivation in 2–5% of neurons, is well 
tolerated. The tolerance of partial loss of X-chromosome 
dosage compensation in the brain in our study raises the 
prospect for therapeutic reactivation of MeCP2 or other 
genes in Rett syndrome and other X-linked genetic disor-
ders in females.
Methods
Mice
Mouse strain carrying  Xisttm5Sado allele (B6;129-Xisttm-
5Sado, Riken Bioresource Center), with a deletion in the 
Xist proximal A repeat [26], was obtained from the Dis-
teche Laboratory at the University of Washington with 
the permissions from the Riken BRC and Dr Takashi 
Sado, who has donated the strain to the Riken BRC. The 
 Xist2lox mouse strain (129-Xisttm2Jae/Mmnc, stock num-
ber 29172-UNC) was obtained from the Mutant Mouse 
Regional Resource Center (MMRRC), a NIH-funded 
strain repository, and was donated to the MMRRC 
by Rudolf Jaenisch, Ph.D., Whitehead Institute. Mice 
strains carrying Nestin-Cre (B6.Cg-Tg(Nes-Cre)1Kln/j, 
stock number 003771) and MeCP2-EGFP transgenes 
 (MeCP2tm3.1Bird/J, stock number 014610) were obtained 
from the Jackson Laboratory. All animals were main-
tained on a C57BL/6 background. Animal work was car-
ried out according to the National Institute of Health and 
institutional guidelines and was approved by the Fred 
Hutchinson Cancer Research Center Institutional Ani-
mal Care and Use Committee.
RNA analysis
Total RNA was extracted from the brains of 2–3-month-
old animals using Trizol LS Reagent (Thermo) using 
manufacturer instructions. RNA integrity was checked 
using an Agilent 2200 TapeStation (Agilent Technologies, 
Inc., Santa Clara, CA) and quantified using a Trinean 
DropSense96 spectrophotometer (Caliper Life Sciences, 
Hopkinton, MA).
RNA-seq libraries were prepared from total RNA using 
the TruSeq RNA Sample Prep Kit v2 (Illumina, Inc., San 
Diego, CA, USA). Library size distribution was validated 
using an Agilent 2200 TapeStation (Agilent Technologies, 
Santa Clara, CA, USA). Additional library QC, blending 
of pooled indexed libraries and cluster optimization were 
performed using Life Technologies’ Invitrogen  Qubit® 
2.0 Fluorometer (Life Technologies-Invitrogen, Carls-
bad, CA, USA). RNA-seq libraries were pooled (8-plex) 
and clustered onto two flow cell lanes. Sequencing was 
performed using an Illumina HiSeq 2500 in rapid mode 
employing a paired-end, 50 base read length (PE50) 
sequencing strategy. Image analysis and base calling were 
performed using Illumina’s Real Time Analysis v1.18 
software, followed by “demultiplexing” of indexed reads 
and generation of FASTQ files, using Illumina’s bcl2fastq 
Conversion Software v1.8.4.
For RT-qPCR, RNA was extracted as above, and cDNA 
was prepared using iScript™ Reverse Transcription 
Supermix for RT-qPCR (BioRad) as per the manufac-
turer’s instructions. Quantitative PCR (qPCR) was per-
formed using Prism 7900HT (Applied Biosystems), with 
Sso Advanced Universal SYBR Green Supermix (BioRad). 
PCR conditions were set up as per the manufacturer’s 
instructions using primers listed in Additional file  5. 
qPCR values were normalized to GAPDH values using 
the ΔΔCt method.
DNA methylation analysis
Methylation analysis was carried out using methylation-
dependent restriction enzyme LpnP1 as described [29]. 
Briefly, DNA, extracted from the brains of 2–3-month-
old female mice using phenol–chloroform (Sigma-
Aldrich) and digested with LpnP1, was used to generate 
sequencing libraries. Because Lpn1 cleaves the DNA at 
a fixed position (N12/N16) downstream from the meth-
ylated cytosine, a symmetrically methylated CpG dinu-
cleotide is expected to generate an approximately 32-bp 
fragment. Pippin Prep (Sage Science, Boston, MA) 
gel system was used to enrich for the fragments of the 
desired size, and the size-selected library was sequenced. 
The pipeline for processing of sequencing data, LpnP1 
filter validation and data analysis was carried out as we 
described previously [29].
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Immunohistochemistry
Brains were removed, fixed in 10% formalin and embed-
ded in paraffin. Four-micron coronal brain sections were 
stained with “Leica Bond Rx” (Leica Biosystems, Buf-
falo Grove, IL). Slides undergoing GFP analyses were 
pretreated with H2 antigen retrieval buffer for 35  min. 
Endogenous peroxidase was blocked with 3% hydrogen 
peroxide for 5  min. A TCT protein block was applied 
for 10  min (0.05  M Tris, 0.15  M NaCl, 0.25% Casein, 
0.1% Tween 20, pH 7.6) and incubated with Anti-GFP 
antibody (1:1000, Invitrogen; A11122) for 60  min. All 
antibodies were then detected using Leica Power Vision 
HRP rabbit-specific polymer (Leica Biosystems; DS9800) 
for 12 min. Nuclear-specific staining was visualized with 
“Refine DAB” (Leica Biosystems; DS9800). A hematoxy-
lin counterstain was then applied. Isotype negative con-
trol antibody-exposed slides were included as controls.
Immunofluorescence
Brains were removed, fixed in 10% formalin and embed-
ded in paraffin. Four-micron coronal brain sections 
were stained with “Leica Bond Rx” (Leica Biosystems, 
Buffalo Grove, IL). For NeuN and GFP dual IF staining, 
slides were pretreated with H1 antigen retrieval buffer 
for 20  min. Avidin/biotin block (Biocare; AB972M) was 
applied for 10  min each followed by 10-min incubation 
in TCT protein block (0.05 M Tris, 0.15 M NaCl, 0.25% 
Casein, 0.1% Tween 20, pH 7.6). Anti-NeuN (1:400, Mil-
lipore; MAB377) biotinylated with goat anti-mouse Fab 
(Jackson 115-067-003) was used for 60  min followed 
by SA-Alexa Fluor 568 (1:200, Invitrogen, catalogue no. 
511226) at 1:200 for 30 min. Another sequential immu-
nofluorescence procedure was followed directly after 
repeat avidin/biotin and TCT protein blocks as described 
above using anti-GFP (1:25, Invitrogen; A11122) for 
60  min and followed with Alexa Fluor 647-conjugated 
goat anti-rabbit (1:50, Invitrogen; A21245).
S100b and GFP dual IF staining were done sequentially 
as described above using anti-S100 (1:100, Dako; Z0628) 
with Alexa Fluor 568-conjugated goat anti-rabbit (1:50, 
Invitrogen; A11011) and Anti-GFP (1:50 Aves Labs Inc.; 
GFP-1010) with Alexa Fluor 647-conjugated donkey 
anti-chicken (1:50, Millipore; AP194SA6). A DAPI coun-
terstain was then applied. Isotype negative control anti-
body-exposed slides were included as controls.
Single IF for specific histone modifications was carried 
out as above using rabbit monoclonal anti-methyl-his-
tone H3 K27-3m (1:50, Cell Signaling; 9733S) and rab-
bit monoclonal anti-H2AK119u1 (1:100, Cell Signaling; 
8240) primary antibodies.
Additional files
Additional file 1. Weights at weaning and at the age of 3 months in 
animals with (Cre+) and without (Cre−) Nestin‑Cre carrying  Xist2lox 
transgene  (Xistmut/  Xist2lox) (upper panel) and in animals without  Xist2lox 
transgene  (Xistmut/ Xist) (lower panel). Mice carrying Nestin‑Cre exhibit 
weight reduction regardless whether they do or do not also carry  Xist2lox 
transgene (**p < 0.01, ***p < 0.001, Student’s t test).
Additional file 2. mRNA levels and DNA methylation of X‑linked genes 
are altered upon Xist deletion. A MeCP2‑EGFP mRNA levels measured by 
RT‑qPCR in the RNA extracted from brains of Nestin‑Cre  Xistmut/MeCP2‑
GFP  Xist2lox females with Xist deletion in the brain (Cre+) relative to the 
MeCP2‑EGFP mRNA level in MeCP2‑EGFP/MeCP2‑EGFP females that carry 
the reporter gene on the Xa (Xa) (n = 3 for each group, error bars indicate 
SD, *** p < 0.001, Student’s t test). B Scatter plot of RNA expression levels 
for genes on autosomes (black) and X‑chromosome (red). The genes on 
X‑chromosome exhibit an upward shift relative to autosomes. C Cumula‑
tive expression plots of fold expression changes in mRNA level among 
controls (Control 1/average (Controls 2 and 3) for genes on autosomes 
(black) and X‑chromosome (red). The two curves are overlapping (p = 0.31, 
Wilcoxon rank‑sum test). D Scatter plot of methylation levels in promoter 
proximal regions of the genes on autosomes (black) and X‑chromosome 
(red). The genes on X‑chromosome exhibit a downward shift relative to 
autosomes.
Additional file 3. Cumulative distribution plots of RNA‑seq data of 
X‑chromosome‑linked genes compared to those on individual autosomes.
Additional file 4. Cumulative distribution plots of CpG island methyla‑
tion of X‑chromosome‑linked genes compared to those on individual 
autosomes.
Additional file 5. Table 1: Primers used in the study.
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